We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
-0.01%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$35.6B
AUM Growth
+$1.38B
(+4%)
Cap. Flow
+$1.82B
Cap. Flow
% of AUM
5.13%
Top 10 Holdings %
Top 10 Hldgs %
28.03%
Holding
2,407
New
40
Increased
606
Reduced
1,352
Closed
406
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$172M |
| 2 |
Honeywell
HON
|
+$160M |
| 3 |
Microsoft
MSFT
|
+$159M |
| 4 |
Amazon
AMZN
|
+$91M |
| 5 |
Tesla
TSLA
|
+$89.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$53.3M |
| 2 |
STMP
Stamps.com, Inc.
STMP
|
+$42.3M |
| 3 |
Magnite
MGNI
|
+$36.1M |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$34.8M |
| 5 |
Etsy
ETSY
|
+$27.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.11% |
| 2 | Consumer Discretionary | 14.43% |
| 3 | Communication Services | 10.72% |
| 4 | Healthcare | 9.96% |
| 5 | Financials | 9.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1951
VistaGen Therapeutics
VTGN
$9.29M
| $68K | ﹤0.01% |
827
-827
| -50% | -$71.9K |
|
|
VIEW
1952
DELISTED
View, Inc. Class A Common Stock
VIEW
| $68K | ﹤0.01% |
209
-157
| -43% | -$55.1K |
|
|
CPRX
1953
DELISTED
Catalyst Pharmaceutical
CPRX
| $66K | ﹤0.01% |
12,442
-12,748
| -51% | -$69.7K |
|
1954
Expro Ltd
XPRO
$1.79B
| $63K | ﹤0.01% |
3,548
-3,634
| -51% | -$61.6K |
|
|
KLDO
1955
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $63K | ﹤0.01% |
11,578
-1,087
| -9% | -$6.74K |
|
|
XXII
1956
22nd Century Group
XXII
$1.47M
| – | – |
0
| – | – |
|
|
AUD
1957
DELISTED
Audacy, Inc.
AUD
| $56K | ﹤0.01% |
15,117
-15,488
| -51% | -$54.2K |
|
|
ASXC
1958
DELISTED
Asensus Surgical, Inc.
ASXC
| $55K | ﹤0.01% |
29,984
-30,719
| -51% | -$69K |
|
1959
KALA BIO
KALA
$11.8M
| $53K | ﹤0.01% |
8
-2
| -20% | -$17.3K |
|
1960
RPC Inc
RES
$1.24B
| $51K | ﹤0.01% |
10,493
-8,618
| -45% | -$36.1K |
|
|
TRUE
1961
DELISTED
TrueCar
TRUE
| $51K | ﹤0.01% |
12,218
-13,313
| -52% | -$61.8K |
|
1962
Nordic American Tanker
NAT
$1.37B
| $50K | ﹤0.01% |
19,550
-19,626
| -50% | -$49.3K |
|
|
GMDA
1963
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $50K | ﹤0.01% |
12,663
+2,026
| +19% | +$10.1K |
|
|
TCDA
1964
DELISTED
Tricida, Inc. Common Stock
TCDA
| $50K | ﹤0.01% |
+10,772
| New | +$44.6K |
|
1965
Atossa Therapeutics
ATOS
$22.8M
| $49K | ﹤0.01% |
1,000
-1,023
| -51% | -$59.5K |
|
1966
Ovid Therapeutics
OVID
$435M
| $49K | ﹤0.01% |
14,511
+2,328
| +19% | +$8.49K |
|
1967
Kartoon Studios
TOON
$34.3M
| $49K | ﹤0.01% |
3,617
-3,706
| -51% | -$57.7K |
|
1968
TETRA Technologies
TTI
$1.23B
| $49K | ﹤0.01% |
15,726
-16,113
| -51% | -$51.7K |
|
1969
Accuray
ARAY
$28.4M
| $47K | ﹤0.01% |
11,853
-12,146
| -51% | -$48.2K |
|
1970
W&T Offshore
WTI
$545M
| $45K | ﹤0.01% |
12,024
-12,323
| -51% | -$44K |
|
1971
Ardelyx
ARDX
$1.24B
| $44K | ﹤0.01% |
33,355
-6,330
| -16% | -$16.9K |
|
|
AMPE
1972
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
| $41K | ﹤0.01% |
83
-81
| -49% | -$37.6K |
|
1973
Lineage Cell Therapeutics
LCTX
$257M
| $40K | ﹤0.01% |
16,071
-15,388
| -49% | -$39.5K |
|
1974
MediciNova
MNOV
$65M
| $40K | ﹤0.01% |
+10,461
| New | +$39.7K |
|
|
URG
1975
Ur-Energy
URG
$485M
| $40K | ﹤0.01% |
23,186
-23,757
| -51% | -$31.8K |
|
Similar funds
ProShare Advisors's Q3 2021 Portfolio in Review
As of Q3 2021, ProShare Advisors held 2,407 positions worth $35.6B, up 4% from $34.2B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
ProShare Advisors deployed $1.82B of net new capital in Q3 2021, opening 40 new positions and adding to 606 existing holdings. Its largest new stake was Sea Limited: 95,823 shares worth $30.5M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Consumer Discretionary and Communication Services.
On the sell side, the largest reduction was Stamps.com, Inc., an estimated $42.3M trimmed.
- ProShare Advisors's largest Q3 2021 buy was Sea Limited: 95,823 shares worth $30.5M.
- ProShare Advisors added most to Apple in Q3 2021, an estimated $172M increase.
- ProShare Advisors's biggest Q3 2021 reduction was Stamps.com, Inc., cutting an estimated $42.3M.
- ProShare Advisors fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $53.3M.
- ProShare Advisors's ten largest holdings make up 28% of its $35.6B portfolio in Q3 2021.
- ProShare Advisors opened 40 new positions and closed 406 in Q3 2021.
- ProShare Advisors's portfolio value rose 4% quarter-over-quarter to $35.6B.
Based on ProShare Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.